Overview Clinical Study of Jaktinib in the Treatment of Patients With Moderate and Severe Atopic Dermatitis Status: Recruiting Trial end date: 2022-12-01 Target enrollment: Participant gender: Summary The purpose of this study is to evaluate the efficacy and safety of Jaktinib in participants with moderate to severe atopic dermatitis. Phase: Phase 2 Details Lead Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd